Therapeutic Potential of Inducible Endogenous Cytoprotective Heme Oxygenase-1 in Mitigating SARS-CoV-2 Infection and Associated Inflammation.
Therapeutic Potential of Inducible Endogenous Cytoprotective Heme Oxygenase-1 in Mitigating SARS-CoV-2 Infection and Associated Inflammation.
复制标题
DOI：
10.3390/antiox11040662
复制
发表时间：
2022-03-30
期刊：
影响因子：
7
通讯作者：
Dhawan, Subhash
中科院分区：
文献类型：
--
作者：
Dhawan, Subhash
近年来，诱导型细胞保护酶血红素加氧酶-1（HO-1）因介导对广泛病毒感染的强细胞抗性而获得了显著的认可，无论病毒类型、病毒株或突变体如何。HO-1不是一种典型的抗病毒药物，针对任何特定的病原体。它是一种“病毒嗜性非依赖性”内源性宿主防御因子，在诱导后提供针对病原体的一般细胞保护。由于HO-1是广泛分布在几乎每个细胞中的细胞内酶，这种独特的宿主因子提供了一类新的针对各种病毒感染的通用宿主防御系统。该观点提出了HO-1依赖性细胞耐药性的药理学评价，以评估其在减轻致命病毒感染方面的潜力，包括目前的严重急性呼吸道综合征冠状病毒-2（SARS-CoV-2）及其变体和突变体。HO-1依赖性细胞对SARS-CoV-2的抵抗力可以补充当前的医疗模式，以更有效地控制COVID-19大流行，特别是在不断出现新的病毒变体和有限的治疗方案来治疗SARS-CoV-2感染和相关的严重健康后果的情况下。
The inducible cytoprotective enzyme heme oxygenase-1 (HO-1) has gained significant recognition in recent years for mediating strong cellular resistance to a broad range of viral infections, regardless of the type of viruses, viral strains, or mutants. HO-1 is not a typical antiviral agent that targets any particular pathogen. It is a “viral tropism independent” endogenous host defense factor that upon induction provides general cellular protection against pathogens. By virtue of HO-1 being widely distributed intracellular enzyme in virtually every cell, this unique host factor presents a novel class of generic host defense system against a variety of viral infections. This Viewpoint proposes pharmacological evaluation of the HO-1-dependent cellular resistance for its potential in mitigating infections by deadly viruses, including the current severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), its variants, and mutants. HO-1-dependent cellular resistance against SARS-CoV-2 can complement current medical modalities for much effective control of the COVID-19 pandemic, especially with constantly emerging new viral variants and limited therapeutic options to treat SARS-CoV-2 infection and associated severe health consequences.
登录
查看更多内容
DOI：
10.1016/j.biopha.2021.111384
发表时间：
2021-05
期刊：
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
影响因子：
--
作者：
Maestro S;Córdoba KM;Olague C;Argemi J;Ávila MA;González-Aseguinolaza G;Smerdou C;Fontanellas A
通讯作者：
Fontanellas A
影响因子：
4.4
作者：
Devadas, Krishnakumar;Dhawan, Subhash
通讯作者：
Dhawan, Subhash
影响因子：
82.9
作者：
Otterbein, LE;Bach, FH;Choi, AMK
通讯作者：
Choi, AMK
影响因子：
64.5
作者：
Korber, Bette;Fischer, Will M.;Montefiori, David C.
通讯作者：
Montefiori, David C.
影响因子：
7.3
作者：
Taefehshokr N;Taefehshokr S;Hemmat N;Heit B
通讯作者：
Heit B